Who Wins the U.S. Clinical AI Market? Abridge, Doximity, OpenEvidence, and Epic Go Head-to-Head
Four AI companies are fighting to own U.S. clinical workflows. We break down how Abridge, Doximity, OpenEvidence, and Epic are building moats — and which formula wins.
MCED FDA Approval Challenges: Why Multi-Cancer Blood Tests Remain Out-of-Pocket
Why MCED tests haven't achieved FDA approval: Analysis of positive predictive value issues, clinical evidence barriers, and diagnostic costs. Plus market potential insights.
HeartFlow IPO Analysis: Medical AI Company IPO Success Story
HeartFlow's IPO marks the first pure-play medical AI company to reach public markets with 99% AI revenue. Analysis of business model, financials, and roadmap for medical AI startups.
How At-Home Digital Diagnostics Are Reshaping Healthcare
Discover how at-home digital diagnostics are enabling early detection and remote monitoring—reshaping the future of personalized healthcare.
